NCT05677659 — "A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia" trial site landscape

Public-registry site landscape for NCT05677659, “A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia”, a ALSP study sponsored by Vigil Neuroscience, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05677659 (registry record)
Study title	A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Official title	A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)
Sponsor	Vigil Neuroscience, Inc.
Condition(s)	ALSP
Phase	PHASE2
Listed sites	10
Site countries	United States, France, Germany, Netherlands, United Kingdom

Patient-friendly overview of this study: eichor.com/study/NCT05677659.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05677659 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →